Abstract:Background Pioglitazone is effective in nonalcoholic steatohepatitis (NASH), but the mechanisms of action are not completely understood. This study was designed to investigate the effects of pioglitazone on hepatic nuclear factor-kappa B (NF-kappa B) and cyclooxygenases-2 (COX-2) expression in NASH rats.Methods Thirty Sprague-Dawley male rats were randomly assigned to a control group (n=10), NASH group (n=10), and pioglitazone treatment group (n=10). Liver tissues were processed for histology by hematoxylin & eosin and Masson stained. Serum alanine aminotransferase (ALT), cholesterol, triglyceride, fasting blood glucose (FBG), fasting insulin (FINS) levels and biochemical parameters of antioxidant enzyme activities, tumor necrosis factor alpha (TNF-alpha), prostaglandin E-2 (PGE(2)) levels in serum and liver were measured. The mRNA and protein expression of peroxisome proliferator-activated receptor gamma (PPAR gamma), NF-kappa B and COX-2 were determined by real-time polymerase chain reaction, Western blotting and immunohistochemistry. One-way analysis of variance (ANOVA) and Wilcoxon's signed-rank test was used for the statistical analysis.Results There were severe steatosis, moderate inflammatory cellular infiltration and fibrosis in NASH rats. After pioglitazone treatment, steatosis, inflammation and fibrosis were significantly improved compared with the NASH group (chi(2)=20.40, P <0.001; chi(2)=20.17, P <0.001; chi(2)=13.98, P=0.002). Serum ALT, cholesterol, triglyceride, FBG, FINS levels were significantly elevated in the NASH group (P <0.05). In the NASH group, total anti-oxidation competence (T-AOC), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-PX) and malondialdehyde (MDA) levels in serum and liver were conspicuous disordered than those parameters in the control group. Meanwhile, TNF-alpha and PGE(2) levels in serum and liver were significantly increased compared with the control group. Immunohistochemistry showed NF-kappa B and COX-2 expression in liver was significantly elevated. However, PPAR gamma level was decreased in the NASH group. Real-time PCR and Western blotting revealed mRNA and protein expression of COX-2 were increased in the NASH group compared with the control group (0.57+/-0.08 vs. 2.83+/-0.24; 0.38+/-0.03 vs. 1.00+/-0.03, P <0.001 and P=0.004, respectively). After pioglitazone intervention, all of those parameters markedly improved (P <0.05 or P <0.01).Conclusion Down-regulating hepatic NF-kB and COX-2 expression, at least in part, is one of the possible therapeutic mechanisms of pioglitazone in NASH rats. Chin Med J 2012;125(13):2316-2321

PPARγ Agonist Pioglitazone Inhibits Microglia Inflammation by Blocking P38 Mitogen-Activated Protein Kinase Signaling Pathways

Rosiglitazone Protects Dopaminergic Neurons Against Lipopolysaccharide-Induced Neurotoxicity Through Inhibition of Microglia Activation

Pioglitazone Suppresses the Lipopolysaccharide-Induced Production of Inflammatory Factors in Mouse Macrophages by Inactivating Nf-Kappa B

Neuroprotective Effects of Pioglitazone in a Rat Model of Permanent Focal Cerebral Ischemia Are Associated with Peroxisome Proliferator-Activated Receptor Gamma-Mediated Suppression of Nuclear Factor-Κb Signaling Pathway

Expression of TNF- and IL- can be suppressed via the PPAR-/mTOR signaling pathway in BV-2 microglia: A potential anti-inflammation mechanism

PPAR‐γ Agonist Pioglitazone Alleviates Inflammatory Response Induced by Lipopolysaccharides in Osteoblast Cells

Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats

Pioglitazone Ameliorates Nonalcoholic Steatohepatitis by Down-Regulating Hepatic Nuclear Factor-Kappa B and Cyclooxygenases-2 Expression in Rats.

Pioglitazone, Ppar Gamma Agonist, Attenuates Experimental Autoimmune Neuritis

Effect of PPARγ on the Analgesic Effects of Pioglitazone

Effects of pioglitazone on the expression of inflammatory cytokines in rat hypertrophic cardiomyocytes

Expression of TNF‐α and IL‐β can be suppressed via the PPAR‐γ/mTOR signaling pathway in BV‐2 microglia: A potential anti‐inflammation mechanism

PIOGLITAZONE INHIBITS HOMOCYSTEINE‐INDUCED MIGRATION OF VASCULAR SMOOTH MUSCLE CELLS THROUGH A PEROXISOME PROLIFERATOR‐ACTIVATED RECEPTOR Γ‐independent MECHANISM

PPAR-γ promotes the polarization of rat retinal microglia to M2 phenotype by regulating the expression of CD200-CD200R1 under hypoxia

Protective effect of pioglitazone on islet cell apoptosis induced by proinflammatory cytokines

[Pioglitazone Decreases the Levels of Inflammatory Cytokines in SD Rats with Traumatic Brain Injury Via Up-Regulating PPARγ].

Pioglitazone, PPARγ Agonist, Attenuates Experimental Autoimmune Neuritis

Pioglitazone Inhibits the Expression of Nicotinamide Adenine Dinucleotide Phosphate Oxidase and P38 Mitogen-Activated Protein Kinase in Rat Mesangial Cells

PPAR-gamma agonists as regulators of microglial activation and brain inflammation

SUMOylation of PPARγ by Rosiglitazone Prevents LPS-Induced NCoR Degradation Mediating Down Regulation of Chemokines Expression in Renal Proximal Tubular Cells

Peroxisome Proliferator-Activated Receptor-Γ Agonists Suppress Inos Expression Induced by LPS in Rat Primary Schwann Cells